Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited (NEU.AX) Stock Overview
Explore Neuren Pharmaceuticals Limited’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
1.5B
P/E Ratio
48.93
EPS (TTM)
$0.23
ROE
0.09%
NEU.AX Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Neuren Pharmaceuticals Limited (NEU.AX) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 38.59, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $19.08.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 48.93 and a market capitalization of 1.5B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.